Immuron Limited - SIC # 2840 -

Ticker Exchange SIC # Website Latest Ticker
IMRN Nasdaq 2840 www.immuron.com.au

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Immuron Limited

Immuron CEO, Steven Lydeamore presentation at Kalkine Media Webinar - Jul 20th, 2026 4:00 am
Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year - Jul 16th, 2026 4:00 am
Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy - Jul 6th, 2026 4:00 am
Presenting on Emerging Growth Conference 92 Day 2 on May 7; Register to live stream - May 6th, 2026 5:00 am
Emerging Growth Research Releases Flash Report on Immuron; Maintains Buy-Extended Rating and Raises Price Target to $4.00 - Apr 22nd, 2026 7:00 am
Immuron Double Digit 3Q Sales Growth - Apr 17th, 2026 4:00 am
Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.90 Price Target - Mar 5th, 2026 8:05 am
Immuron CEO, Steven Lydeamore presentation at Coffee Microcaps Conference - Mar 5th, 2026 4:00 am
Immuron Reports HY26 Results and Strategic Reset - Feb 25th, 2026 4:00 am
Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.50 Price Target - Jan 22nd, 2026 4:00 am
Presenting on Emerging Growth Conference 89 Day 2 on January 22; Register to live stream - Jan 21st, 2026 5:00 am
Immuron Reports Continued Sales Growth - Jan 19th, 2026 4:00 am
Immuron (IMRN) Struggles After Announcing Trial Results - Dec 15th, 2025 10:36 am
Immuron New U.S. Department of Defense Award & Clinical Trial Update - Dec 3rd, 2025 4:00 am
Immuron IMM-529 IND approved by FDA - Nov 5th, 2025 4:00 am
Immuron Announces Clinical Trial Update - Oct 31st, 2025 4:00 am
Presenting on Emerging Growth Conference 87 Day 1 on October 22. Register to live stream. - Oct 21st, 2025 5:00 am
Emerging Growth Research Initiates Coverage on Immuron Limited with a Buy-Extended Rating and $4.00 Price Target - Oct 17th, 2025 9:07 am
Immuron Q1 FY26 YoY growth - Oct 13th, 2025 4:00 am
Immuron Submits IMM-529 IND to FDA - Oct 8th, 2025 4:00 am